XY Capital Ltd Buys Shares of 27,755 Mesoblast Limited (NASDAQ:MESO)

Key Points

• XY Capital Ltd has acquired a new stake in Mesoblast Limited, purchasing 27,755 shares valued at approximately $346,000 in the first quarter.
• Several hedge funds increased their stakes in Mesoblast, with Geode Capital Management growing its position by 65.5% in the fourth quarter.
• Mesoblast shares are currently rated as a "Moderate Buy" with an average price target of $18.00, despite a recent downgrade from Jefferies Financial Group.

XY Capital Ltd bought a new position in Mesoblast Limited (NASDAQ:MESO - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,755 shares of the company's stock, valued at approximately $346,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of MESO. Barclays PLC purchased a new stake in Mesoblast in the 4th quarter valued at $38,000. JPMorgan Chase & Co. bought a new position in shares of Mesoblast during the 4th quarter worth $50,000. BNP Paribas Financial Markets lifted its holdings in Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in Mesoblast during the 4th quarter worth about $88,000. Finally, Advisors Preferred LLC raised its holdings in shares of Mesoblast by 224.9% in the 1st quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after acquiring an additional 3,169 shares in the last quarter. Institutional investors own 1.43% of the company's stock.

Mesoblast Stock Up 1.9%

NASDAQ:MESO traded up $0.28 during trading hours on Tuesday, reaching $14.98. 89,105 shares of the company traded hands, compared to its average volume of 281,011. Mesoblast Limited has a 1 year low of $6.00 and a 1 year high of $22.00. The business's 50-day moving average price is $12.72 and its two-hundred day moving average price is $13.26. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MESO shares. Canaccord Genuity Group raised Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.